AIDS Group Calls Out ‘Greedy’ GSK Over HIV Drug Price In Trinidad And Tobago

The Non-Profit Urged The Local Government To Issue A Compulsory License For Tivicay

 
• By Urtė Fultinavičiūtė

Even though the cost of Tivicay is 25 times higher in Trinidad and Tobago compared to other countries in the region, GSK says that its pricing is based on several factors such as country income classification.

Red ribbon, white pills and bottle on blue background, concept picture about HIV and AIDS
• Source: Shutterstock

The AIDS Healthcare Foundation has pointed fingers at “greedy” GSK over the pricing of its human immunodeficiency virus drug Tivicay (dolutegravir) in Trinidad and Tobago, stating that the drug “costs 25 times more than available biosimilar generics in neighboring Caribbean countries.”

The global non-profit organization has urged the government of Trinidad and Tobago to consider issuing a compulsory license for Tivicay, which would allow

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products